Abstract：Objective To analyze the clinical significance of endovascular stents in treatment of hepatic vein type Budd-Chiari syndrome.Methods Newcastle-Ottawa Scale assessment method was used by carrying out the computer-based retrieval and collecting the documents about the endovascular stents in treatment of hepatic vein type Budd-Chiari syndrome at home and abroad, the searching time limit was set from January 1992 to July 2014, all of collected data were analyzed and summarized, and the Meta analysis was conducted for the diameter stenosis and blocking rate of postoperative endovascular stents and percutaneous transluminal angioplasty.Results After systematic retrieval based on search strategies, according to inclusion criteria, there were 6 Chinese papers and one English paper included, with a total of 534 patients. The Meta analysis was conducted for the diameter stenosis and blocking rate of postoperative endovascular stents and percutaneous transluminal angioplasty in those included papers. The results showed that, after combining the diameter stenosis and blocking rate of postoperative percutaneous transluminal angioplasty and endovascular stents, the tests for heterogeneity revealed that it had the significant heterogeneity (χ2=15.821, P＜0.05, I2=62%). After using a random-effect model, the results showed that the merged RR value was 0.63 (95%CI:0.21-1.88, P＞0.05), which indicated that the diameter stenosis and blocking rate of postoperative endovascular stents and percutaneous transluminal angioplasty in short-and medium-term had no significant differences.Conclusions Endovascular stents have advantages of a high success rate, higher safety and minimal invasion with definite efficacy in treatment of hepatic vein type Budd-Chiari syndrome. The diameter stenosis and blocking rate of postoperative endovascular stents and percutaneous transluminal angioplasty in short-and medium-term had no significant differences. For patients with unclear therapeutic effects in percutaneous transluminal angioplasty or with repeated percutaneous transluminal angioplasty, they may consider the endovascular stent therapy.
马强,余朝文,任佩,孙喆. 血管内支架治疗肝静脉型布加综合征临床价值的Meta分析[J]. 中华解剖与临床杂志, 2016, 21(1): 46-49.
Ma Qiang, Yu Chaowen, Ren Pei, Sun Zhe. The clinical value of endovascular stent in treatment of hepatic vein-type Budd-Chiari syndrome: a Meta analysis. Chinese Journal of Anatomy and Clinics, 2016, 21(1): 46-49.
Wang ZG, Zhu Y, Wang SH, et al. Recognition and management of Budd-Chiari syndrome: report of one hundred cases[J]. J Vasc Surg, 1989, 10(2): 149-156. DOI:10.1016/0741-5214(89)90348-0
Qiao T, Liu CJ, Liu C, et al. Interventional endovascular treatment for Budd-Chiari syndrome with long-term follow-up[J]. Swiss Med Wkly, 2005, 135(21/22): 318-326
[5]
Abdel-Atty MY, Farges O, Jagot P, et al. Laparoscopy extends the indications for liver resection in patients with cirrhosis[J]. Br J Surg, 1999, 86(11): 1397-1400. DOI:10.1046/j.1365-2168.1999.01283.x
[6]
Chen HY, Juan CC, Ker CG. Laparoscopic liver surgery for patients with hepatocellular carcinoma[J]. Ann Surg Oncol, 2008, 15(3): 800-806. DOI:10.1245/s10434-007-9749-1
Li TX, Zhai ST, Pang ZG, et al. Feasibility and midterm outcomes of percutaneous transhepatic balloon angioplasty for symptomatic Budd-Chiari syndrome secondary to hepatic venous obstruction[J]. J Vasc Surg, 2009, 50(5): 1079-1084. DOI:10.1016/j.jvs.2009.06.049
Kathuria R, Srivastava A, Yachha SK, et al. Budd-Chiari syndrome in children: clinical features, percutaneous radiological intervention, and outcome[J]. Eur J Gastroenterol Hepatol, 2014, 26(9): 1030-1038. DOI:10.1097/MEG.0000000000000144
[13]
Han G, Qi X, Zhang W, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center[J]. Radiology, 2013, 266(2): 657-667. DOI:10.1148/radiol.12120856
[14]
Schwartz SM, Daling JR, Shera KA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study[J]. J Clin Oncol, 2001, 19(7): 1906-1915
[15]
Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome[J]. Gut, 2006, 55(6): 878-884. DOI:10.1136/gut.2005.071423
[16]
Lee BB, Villavicencio L, Kim YW, et al. Primary Budd-Chiari syndrome: outcome of endovascular management for suprahepatic venous obstruction[J]. J Vasc Surg, 2006, 43(1): 101-108. DOI:10.1016/j.jvs.2005.09.003
2016, Vol. 21 
